-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In clinical practice, the difference in the efficacy of each Janus kinase (JAK) inhibitor in the treatment of rheumatoid arthritis (RA) is not clear
In clinical practice, the difference in the efficacy of each Janus kinase (JAK) inhibitor in the treatment of rheumatoid arthritis (RA) is not clear
The study compared the effects of TOFA (n=156) and BARI (n=138) on patients with RA
After adjustment, there was no significant difference in patient characteristics between the TOFA group and the BARI group
After adjustment, there was no significant difference in patient characteristics between the TOFA group and the BARI group
It can be seen that BARI has better clinical efficacy than TOFA, and the safety of the two is equivalent
Original source:
Original source: Original source:Yusuke Miyazaki.
Yusuke Miyazaki.
Leave a message here